NCT05831891View on ClinicalTrials.gov

Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2026

Conditions
Non-clear Renal Cell Carcinoma
Interventions
DRUG

Fruquintinib combined with Serplulimab

Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w

Trial Locations (1)

200123

RECRUITING

Renji Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

lead

RenJi Hospital

OTHER